The Zacks analyst believes that the planned launch of an in-house ad tech platform next year signals the ... However, the company's high debt load is a concern. Kisqali, Pluvicto Drive Novartis (NVS) ...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

Another point of concern for BofA Securities is the potential impact of the upcoming Kisqali patent litigation outcome. Should the decision fall unfavorably for Novartis, it could lead to a ...

At close: November 8 at 3:00 PM EST ...